310 related articles for article (PubMed ID: 19462824)
21. Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.
Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):407-12. PubMed ID: 19211197
[TBL] [Abstract][Full Text] [Related]
22. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
[TBL] [Abstract][Full Text] [Related]
23. Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: predictive factors.
Park SC; Rim JS; Choi HY; Kim CS; Hong SJ; Kim WJ; Lee SE; Song JM; Yoon JH
Int J Urol; 2009 Aug; 16(8):670-5. PubMed ID: 19602007
[TBL] [Abstract][Full Text] [Related]
24. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
25. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
Kojima S; Suzuki H; Akakura K; Shimbo M; Ichikawa T; Ito H
J Urol; 2004 Feb; 171(2 Pt 1):679-83. PubMed ID: 14713785
[TBL] [Abstract][Full Text] [Related]
26. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
[TBL] [Abstract][Full Text] [Related]
27. Complete response, as determined by prostate-specific antigen level, to chlormadinone acetate withdrawal persisting longer than 2 years in patients with advanced prostate cancer: two case reports.
Noguchi K; Teranishi J; Uemura H; Fujikawa N; Saito K; Murai T
Int J Urol; 2006 Sep; 13(9):1259-61. PubMed ID: 16984567
[TBL] [Abstract][Full Text] [Related]
28. Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate.
Akakura K; Akimoto S; Furuya Y; Ito H
Eur Urol; 1998; 33(6):567-71. PubMed ID: 9743699
[TBL] [Abstract][Full Text] [Related]
29. Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: report of 52 cases and literature review.
Matsumoto K; Hagiwara M; Hayakawa N; Tanaka N; Ito Y; Maeda T; Ninomiya A; Nagata H; Nakamura S
Asian Pac J Cancer Prev; 2014; 15(8):3645-9. PubMed ID: 24870772
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):983-9. PubMed ID: 19409726
[TBL] [Abstract][Full Text] [Related]
31. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
Kassouf W; Tanguay S; Aprikian AG
J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
[TBL] [Abstract][Full Text] [Related]
32. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
Arlen PM; Gulley JL; Todd N; Lieberman R; Steinberg SM; Morin S; Bastian A; Marte J; Tsang KY; Beetham P; Grosenbach DW; Schlom J; Dahut W
J Urol; 2005 Aug; 174(2):539-46. PubMed ID: 16006888
[TBL] [Abstract][Full Text] [Related]
33. [Prostate cancer--treatment of hormone independent cancer].
Yamanaka H; Imai K; Suzuki T; Masimo T
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2390-5. PubMed ID: 1719940
[TBL] [Abstract][Full Text] [Related]
34. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
[TBL] [Abstract][Full Text] [Related]
35. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy.
Clark PE; Hall MC; Borden LS; Miller AA; Hu JJ; Lee WR; Stindt D; D'Agostino R; Lovato J; Harmon M; Torti FM
Urology; 2006 Jun; 67(6):1257-61. PubMed ID: 16765186
[TBL] [Abstract][Full Text] [Related]
36. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.
Bogdanos J; Karamanolakis D; Milathianakis C; Repousis P; Tsintavis A; Koutsilieris M
Anticancer Res; 2003; 23(2C):1757-62. PubMed ID: 12820454
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
[TBL] [Abstract][Full Text] [Related]
38. [Total androgen blockade for prostate cancer].
Kagebayashi Y; Ozono S; Takashima K; Yoshikawa M; Hayashi Y; Kaneko Y; Maruyama Y; Hirao Y; Okajima E
Hinyokika Kiyo; 1997 Mar; 43(3):197-201. PubMed ID: 9127754
[TBL] [Abstract][Full Text] [Related]
39. [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
Akakura K; Furuya Y; Ito H
Nihon Rinsho; 1998 Aug; 56(8):2124-8. PubMed ID: 9750520
[TBL] [Abstract][Full Text] [Related]
40. [Long term survival results in advanced prostate cancer treated with combined androgen blockade].
Zhang SG; Wang YH; Ding Y; Wu Y
Zhonghua Nan Ke Xue; 2005 Oct; 11(10):770-1, 774. PubMed ID: 16281513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
